drugset
Drugs / K-NK002
last change Nov 2023 re-read 3 minutes ago

K-NK002

Cell therapy

Developed for
acute myeloid leukemia · myelodysplastic syndrome
Investigated by
Blood and Marrow Transplant Clinical Trials Network · Kiadis Pharma · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH)

Trials 1

today NCT04395092 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04395092 Nov 2020 → Nov 2022 acute myeloid leukemia, myelodysplastic syndrome Kiadis Pharma Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as K-NK002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04395092 ↗
Modality Cell therapy “K-NK002 is a NK cell product derived from peripheral blood leukocytes collected from a related donor (HLA-haploidentical matched) and enriched for NK cells” NCT04395092 ↗
Route Intravenous “K-NK002 will be administered intravenous (IV)” NCT04395092 ↗